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Abstract
Background: The effects of acute tryptophan depletion on human decision-making suggest that serotonin modulates the processing 
of rewards and punishments. However, few studies have assessed which of the many types of serotonin receptors are responsible.
Methods: Using a within-subject, double-blind, sham-controlled design in 26 subjects, we examined whether individual 
differences in serotonin system gene transcription, measured in peripheral blood, predicted the effect of acute tryptophan 
depletion on decision-making. Participants performed a task in which they chose between successive pairs of fixed, lower-
stakes (control) and variable, higher-stakes (experimental) gambles, each involving wins or losses. In 21 participants, mRNA 
from 9 serotonin system genes was measured in whole blood prior to acute tryptophan depletion: 5-HT1B, 5-HT1F, 5-HT2A, 
5-HT2B, 5-HT3A, 5-HT3E, 5-HT7 (serotonin receptors), 5-HTT (the serotonin transporter), and tryptophan hydroxylase 1.
Results: Acute tryptophan depletion did not significantly influence participants’ sensitivity to probability, wins, or losses, 
although there was a trend for a lower tendency to choose experimental gambles overall following depletion. Significant 
positive correlations, which survived correction for multiple comparisons, were detected between baseline 5-HT1B mRNA 
levels and acute tryptophan depletion-induced increases in both the overall tendency to choose the experimental gamble 
and sensitivity to wins. No significant relationship was observed with any other peripheral serotonin system markers. 
Computational analyses of decision-making data provided results consistent with these findings.
Conclusions: These results suggest that the 5-HT1B receptor may modulate the effects of acute tryptophan depletion on risky 
decision-making. Peripheral levels of serotonin markers may predict response to treatments that act upon the serotonin 
system, such as selective serotonin reuptake inhibitors.
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Introduction
The serotonin (5-HT) system has long been implicated in deci-
sion-making (Soubrie et al., 1986; Deakin and Graeff, 1991), yet 
its precise role in reward and punishment processing remains 
unclear (Dayan and Huys, 2009; Boureau and Dayan, 2011). 
Several studies have attempted to characterize this relation-
ship by manipulating 5-HT levels via the dietary technique of 
acute tryptophan depletion (ATD; see Faulkner and Deakin, 
2014 for a review). The results of such studies are mixed, but 
a common finding is that ATD can influence the process-
ing of punishments on reaction time tasks (e.g., Cools et  al., 
2008; Crockett et al., 2012; Robinson et al., 2012). For example, 
Crockett et al. (2009) showed that ATD abolished punishment-
induced behavioral inhibition on a go/no-go task; and Geurts 
et al. (2013) extended these results, reporting that ATD led to 
decreased punishment-induced instrumental inhibition while 
reversing the inhibitory effect of aversive (but not appetitive) 
Pavlovian stimuli on instrumental responding (replicated by 
Hebart and Glascher, 2014). Studies of the effects of ATD on 
reward processing are also mixed. While Cools et  al. (2005) 
found that ATD attenuated reinforcement-related speeding on 
a cued-reinforcement reaction time task (partially confirmed 
by Roiser et al., 2006), den Ouden et al. (2014) reported that ATD 
decreased behavioral inhibition to a similar extent for both 
rewarding and punishing stimuli on a modified cued-reinforce-
ment reaction time task, though only in a high-feedback prob-
ability condition.
Studies that have examined the effect of ATD on probabilis-
tic choice tasks have also produced mixed results. Rogers et al. 
(2003) administered a gambling task that assessed participants’ 
choices as a function of (1) probability, (2) the magnitude of 
expected gains, and (3) the magnitude of expected losses. The 
authors found that ATD altered participants’ decision-making 
by attenuating their discrimination between large and small 
wins, while the processing of losses and probability was unaf-
fected. Seymour et al. (2012) observed a result weakly consist-
ent with this using a probabilistic 4-armed bandit task: ATD 
altered the exchange rate by which rewards and punishments 
were compared, with this alteration being driven by a decrease 
in the subjective value of rewards. However, Rogers et al. (1999b) 
observed an ATD-induced reduction in high probability choices 
on the Cambridge Gamble Task, while Talbot et al. (2006) found 
the opposite result. The discordant results between these latter 
2 studies suggest a need to examine the potential role of indi-
vidual differences in 5-HT function in moderating the effects 
of ATD.
Very few studies have attempted to delineate the roles of 
specific receptors in the effects of 5-HT on decision-making 
(Homberg, 2012). In humans, Macoveanu et  al. (2013) reported 
that administration of the 5-HT2A antagonist ketanserin 
increased risk aversion, and Faulkner et  al. (2014) showed a 
positive correlation in humans between hippocampal 5-HT1A 
receptor availability and sensitivity to probability on the gam-
bling task used in Rogers et al. (2003). These studies raise the 
possibility that specific 5-HT receptor subtypes may moderate 
the effect of ATD on decision-making. However, this is difficult 
to test directly in humans due to the high cost and invasive 
nature of molecular imaging techniques such as positron emis-
sion tomography.
Studies have shown that dopamine (Illani et  al., 2001) and 
serotonin (Ye et al., 2014) receptor mRNA levels in the blood cor-
respond to levels in the brain. This was exploited by Ersche et al. 
(2011), who examined peripheral levels of mRNA pertaining to 
the dopamine receptor 3 (D3) and D4 genes in order to under-
stand variability in response to dopamine agonist treatment. 
Variation in peripheral levels of D3 mRNA explained over one-
quarter of the variation in improvements on a spatial working 
memory task due to administration of the D2/3 receptor agonist 
pramipexole. Based on this finding, we reasoned that measur-
ing individual differences in levels of 5-HT receptor mRNA in 
peripheral blood might help explain variation in the effects 
of ATD.
The current study aimed to test the effects of ATD on 
decision-making and to examine whether individual differ-
ences in peripheral 5-HT system gene mRNA levels moder-
ate such effects. Whole-blood mRNA levels were measured 
for 9 5-HT-related genes: 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT3A, 
5-HT3E, 5-HT7 (serotonin receptors), 5-HTT (the serotonin 
transporter), and tryptophan hydroxylase 1 (TPH1). Both 
standard and computational analyses of decision-making 
behavior were utilized. Based on previous results examining 
decision-making under ATD, we predicted that participants 
would display decreased ability to utilize information per-
taining to rewards following ATD; we also predicted that such 




Thirty participants were recruited via online advertisements. All 
participants gave written informed consent and the University 
College London (UCL) Research Ethics committee approved the 
study. Exclusion criteria (assessed by the Mini International 
Neuropsychiatric Inventory: Sheehan et al., 1998) included past/
present major depressive disorder, bipolar disorder, psychosis, 
anxiety disorders, psychotropic medication usage, substance/
alcohol dependence or recent (<6 months) abuse, or any neuro-
logical disorder. Participants were medically healthy and none 
reported taking regular medication for any illness. Both men 
Significance Statement
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and women were admitted to the study. However, (female) par-
ticipants’ menstrual cycle stage was not recorded.
Following exclusions (detailed in the supplementary Online 
Materials), data from 22 participants were analyzed to assess 
the biochemical effect of the ATD procedure, data from 26 
participants were analyzed to assess ATD effects on decision-
making, and data from 21 participants were analyzed to assess 
relationships between peripheral 5-HT system mRNA levels and 
ATD-induced effects on decision-making.
Procedure
Testing took place at the Wellcome Trust Centre for 
Neuroimaging, UCL. Participants completed 2 testing sessions 
(ATD and sham) at least 1 week apart and fasted for 8 hours 
prior to the start of each testing session. At the start of each 
study day (T0), blood samples were obtained to determine 
baseline plasma amino acid levels and 5-HT system periph-
eral mRNA levels. Participants then completed the State Trait 
Anxiety Inventory (STAI; Speilberger et al., 1987) and ingested an 
amino acid drink either selectively lacking (TRP-) or containing 
(sham depletion, TRP+) tryptophan, in a within-subjects, double-
blind, sham-controlled design. The order of drink administra-
tion was counterbalanced across participants. Participants then 
rested (and continued to fast) at the testing site for the next 5 
hours. Participants then completed the STAI, and blood samples 
were obtained once more at the end of this 5-hour period (T5) 
to determine plasma amino acid levels post-treatment before 
the gambling task was performed (as part of a larger cogni-
tive battery; data for other tasks will be reported elsewhere). 
Participants were then provided with a tryptophan-rich meal 
before leaving the laboratory.
The concentrations of each amino acid in the drink were 
based upon those reported in Young et al. (1985) and are reported 
in the supplementary Online Materials, together with the meth-
ods used for plasma amino acid analysis.
Gambling Task
Participants completed 80 trials, during each of which they had 
to make a choice between 2 gambles. Each gamble was repre-
sented as a bar, the height of which indicated the probability 
of winning or losing a number of points. The magnitudes of 
potential gains and losses were displayed in green at the top 
and in red at the bottom of each bar, respectively (supplemen-
tary Figure 1). One of the gambles, called the control gamble, was 
the same on every trial. It involved a lower-stakes 50% chance 
of winning or losing 10 points. The other, experimental, gamble 
involved either a 75% or 25% chance of winning 80 or 20 points 
and the inverse chance of losing 80 or 20 points. There were 
thus 8 trial types in total, which are described in supplementary 
Table 1. Two additional trial types, “gains only” and “losses only,” 
were also administered, but data from these were not included 
in the analyses.
There were 3 main basic (i.e., noncomputational) outcomes 
variables from this task, namely the proportion of experimental 
gambles chosen over the control gamble as a function of: (1) the 
probability of winning (high vs low probability of winning); (2) 
the magnitude of potential win (high vs low magnitude); and (3) 
the magnitude of potential loss (high vs low magnitude) (sup-
plementary Figure 1), which we term “sensitivity” to probability, 
win, and loss after Rogers et al. (2003). Each of these 3 measures 
was calculated by taking the difference between the proportion 
of experimental gamble choices when each of these factors was 
high compared with when it was low. For clarity in presenting 
the results, the negative of loss sensitivity is depicted.
Questionnaire
The STAI is a 40-item, self-rating anxiety measure; the first 20 
items identify state anxiety, and the second 20 identify trait 
anxiety. Participants must give a score of 1 (“do not agree at all”), 
2 (“agree somewhat”), 3 (“agree moderately”), or 4 (“very much 
agree”). Scores are then summed to give their state and trait 
anxiety scores.
mRNA Extraction and Analysis
Blood samples (4 mL) were drawn into PAXgene tubes (Qiagen) 
to maximize the stability of the mRNA and avoid potential deg-
radation. Levels of plasma mRNA were examined for 5-HT1A, 
5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3A, 
5-HT3B, 5-HT3C, 5-HT3D, 5-HT3E, 5-HT4, 5-HT5A, 5-HT6, 5-HT7, 5-HTT, 
TPH1, and TPH2. However, mRNA levels were detectable for all 
subjects for only 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT3A, 5-HT3E, 
5-HT7, 5-HTT, and TPH1, and as such only these transcripts were 
included in the correlational analyses. Details of sample pro-
cessing and mRNA measurement are provided in the SOM.
Statistical Analysis
Data were analyzed using IBM SPSS Statistics (http://www-01.
ibm.com/software/analytics/spss/products/statistics). An arc-
sine (square root) transform was applied to probability data 
prior to analysis. The order of treatment administration (i.e., 
TRP- in week 1 or week 2) was added as a between-subjects fac-
tor for all analyses.
Plasma amino acid data were analyzed using a 2 x 2 ANOVA, 
with treatment constituting 2 levels (ATD and sham) and time 
constituting 2 levels (T0 and T5). Decision-making data were 
analyzed using a 2 x 2 x 2 x 2 ANOVA, with treatment constituting 
2 levels, and each of probability, win, and loss constituting 2 lev-
els (high and low); based on our a priori hypotheses, we focused 
on the effects of probability, win, and loss and their interac-
tions with treatment. Mood data from the STAI were analyzed 
using a 2 x 2 ANOVA, with treatment constituting 2 levels and 
time constituting 2 levels (T0 and T5). Significant interactions 
were interrogated by constructing the simple main or interac-
tion effects. A  significance threshold of alpha  =  0.05 (2-tailed) 
was adopted for all analyses, while .05 < P < .10 was considered 
a trend towards significance. Relationships between peripheral 
5-HT system mRNA levels and ATD-induced changes in deci-
sion-making behavior were analyzed using Pearson’s correla-
tion coefficients. Bonferroni correction (BC; for 9 transcripts*4 
decision-making measures = 36 tests) was applied to the corre-
lational analyses.
Finally, exploratory analyses were conducted to examine 
whether the effects of treatment, and correlations between 
treatment-induced changes in task performance and seroto-
nin gene transcription, were moderated by gender. To examine 
the former, a 2 x 2 x 2 x 2 ANOVA was performed, with treatment 
(ATD and sham) and each of probability, win, and loss (high and 
low) as within-subjects factors and gender added as a between-
subjects factor. The effect of gender on relationships between 
peripheral 5-HT system mRNA levels and ATD-induced changes 
in decision-making behavior was analyzed using general linear 
models, with the treatment-induced change in sensitivity to 
probability, win sensitivity, loss sensitivity, and the proportion of 
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experimental gambles acting as dependent variables in separate 
ANOVAs, peripheral 5-HT system mRNA levels added as contin-
uous covariates, and gender added as a between-subjects factor. 
The interaction between gender and mRNA levels was included 
to test for modulatory effects.
Power Analysis
For the effects of ATD upon decision-making, with data from 26 
participants in a within-subjects design, this study had approxi-
mately 95% power to detect an effect size of d~0.75 (large, Cohen 
et  al., 1988), comparable with that observed in the study of 
Rogers et al. (2003) (using a between-subjects design). For cor-
relations between peripheral 5-HT system mRNA levels and 
the effect of ATD on decision-making, with data from 21 par-
ticipants, this study had 80% power to detect a correlation of 
r~0.55, comparable with the correlation between peripheral D3 
mRNA levels and pramipexole-induced improvement in work-
ing memory observed by Ersche et al. (2011).
Computational Analysis
To explore behavior on the decision-making task in more detail, 
we performed a hierarchical Bayesian mixed-effects analysis 
of participants’ data (Daw, 2009), fitting a set of 5 increasingly 
complex, parametrized logistic regression models (supplemen-
tary Table 2). The models included different components involv-
ing information about probability, reward, expected values, and 
other factors.
All statistical analyses were based on permutation tests with 
empirical null distributions created by randomizing TRP status 
across testing sessions. Posterior distributions over the parame-
ters for each model for each participant and condition were esti-
mated using a Hamiltonian Monte Carlo sampler, implemented 
in PyStan (http://mc-stan.org/pystan.html). We additionally 
generated synthetic data from our winning model to assess the 
fidelity with which it could recapitulate the statistical character-
istics of the original behavior. Further details are provided in the 
supplementary Online Material.
Results
Plasma Amino Acid Concentrations
Total tryptophan concentration (nmol/mL) in the plasma was 
lower overall on the TRP- day than the TRP+ day (significant 
main effect of treatment: F(1,20) = 160.712, P < .001) and was 
lower overall at T5 than T0 (significant main effect of time: 
F(1,20) = 9.189, P = .007). As expected, there was a significant 
treatment-by-time interaction (F(1,20) = 133.174, P < .001): plasma 
tryptophan concentration increased 126.5% from T0 to T5 on 
the TRP+ day (mean T0 = 56.16, SD = 12.50, mean T5 = 127.24, 
SD = 40.42, t(21) = 7.994, P < .001) and decreased 73.3% from T0 to 
T5 on the TRP- day (mean T0 = 60.39, SD = 13.97, mean T5 = 16.12, 
SD = 5.66, t(21) = 19.239, P < .001). There was no difference in mean 
tryptophan concentrations between TRP+ and TRP- days at T0 
(t[21] = 1.343, P = .194). There was no effect of drink order on tryp-
tophan levels (F(1,20) = .211, P = .651), and no significant interac-
tion with order.
The tryptophan:large neutral amino acid (LNAA) ratio was 
also lower on the TRP- day than the TRP+ day (significant main 
effect of treatment: F(1,20) = 102.475, P < .001) and was lower at T5 
than T0 (significant main effect of time: F(1,20) = 29.972, P < .001). 
Again, there was an expected treatment-by-time interaction 
(F(1,20) = 73.105, P < .001): the plasma ratio increased 17.2% from T0 
to T5 following TRP+, which showed a trend towards significance 
(mean T0 = 0.156, SD = 0.046, mean T5 = 0.189, SD = .015, t(21) = 1.931, 
P = .067), and significantly decreased 85.1% from T0 to T5 follow-
ing TRP- (mean T0 = 0.166, SD = 0.054, mean T5 = 0.025, SD = 0.012, 
t(21) = 13.860, P < .001). Again, there was no difference between the 
days on the plasma ratio measure at T0 (t[21] = 0.937, P = .359), no 
effect of drink order on the ratio measure (F(1,20) = .541, P = .470), 
and no significant interaction with order.
Decision-Making Task: Proportionate Choice
Choice data are displayed in Table  1A. Participants chose the 
experimental gamble significantly more often when the prob-
ability of winning was high (F(1,24) = 223.812, P < .001), when the 
amount that could be won was high (F(1,24) = 34.798, P < .001), 
and when the amount that could be lost was low (F(1,24) = 34.364, 
P < .001).
Following TRP- participants displayed a trend towards choos-
ing the experimental gamble less often compared with TRP+ 
(F(1,24) = 3.532, P = .072). Examining each sensitivity separately, 
there was no effect of treatment upon sensitivity to probability 
(F(1,24) = 0.668, P = .422), wins (F(1,24) = 0.210, P = .651), or losses 
(F(1,24) = 0.143, P = .708).
There was no effect of drink order on participants’ overall 
choices (F(1,24) = 0.007, P = .936). There was a significant drink 
order-by-treatment-by-probability interaction (F(1,24) = 6.445, 
P = .018), indicating a practice effect by which sensitivity to prob-
ability was higher on the second testing session. No interactions 
between order, treatment, and either wins or losses approached 
significance (both P > .169).
Deliberation Times
Deliberation time data are displayed in Table  1B. Participants 
were significantly quicker to respond when the probability of 
winning was high (F(1,24) = 7.437, P = .012) and when the magni-
tude of potential losses was low (F(1,24) = 6.887, P = .015), but the 
effect of the magnitude of potential wins on reaction time was 
nonsignificant (F(1,24) = .017, P = .898).
Table 1. Proportion (SD) of Choices of the Experimental Gamble (A), and Mean (SD) Deliberation Times (ms; B) as a Function of the Probability 
of Winning, the Magnitude of Potential Wins, and the Magnitude of Potential Losses under ATD (TRP-) and Sham (TRP+)
Probability of Winning Magnitude of Wins Magnitude of Losses
A High Low Large Small Large Small
TRP- 0.77 (.18) 0.18 (.19) 0.55 (.12) 0.39 (.12) 0.38 (.16) 0.56 (.10)
TRP+ 0.84 (.15) 0.17 (.14) 0.58 (.10) 0.44 (.12) 0.42 (.14) 0.60 (.09)
B High Low Large Small Large Small
TRP- 1766 (1015)  2013 (1055) 1902 (1078) 1878 (1008) 1935 (1066) 1845 (1018)
TRP+ 1769 (993) 1983 (930) 1882 (1006) 1871 (930) 1970 (993) 1793 (935)
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There was no main effect of treatment on participants’ delib-
eration times (F(1,24) = 1.102, P = .304). Treatment did not signifi-
cantly influence participants’ deliberation times as a function 
of probability, potential wins, or potential losses (all interac-
tions: P > .321). There was a significant drink order-by-treatment 
interaction on participants’ deliberation times (F(1,24) = 14.625, 
P = .042), indicating a practice effect by which responses were 
faster on the second testing session. There was also a significant 
drink order-by-treatment-by-loss interaction (F(1,24) = 5.446, 
P = .028). The increase in deliberation times on high potential 
loss trials was attenuated on the second testing session, again 
indicating a practice effect. No interactions between order, treat-
ment, and either probability or wins approached significance 
(both P > .292).
Effect of Acute Tryptophan Depletion on Anxiety
There was no significant main effect of treatment upon par-
ticipants’ state anxiety scores (state STAI: F(1,24) = .121, 
P = .732). There was also no main effect of time on state STAI 
(F(1,24) = 2.211, P = .153). However, there was a significant 
treatment*time interaction (F(1,24) = 6.651, P = .019), with post-
hoc paired t tests revealing that while scores did not differ 
significantly between T0 and T5 on the TRP+ day (mean (SD) 
T0 TRP+ = 10.71 (9.13), T5 TRP+ = 10.33 (8.32)), participants’ state 
STAI scores increased significantly from T0 to T5 on the TRP- 
day (T0 TRP- = 9.86 (5.94), T5 TRP- = 12.00 (6.72), t(25) = 2.918, 
P = .009).
Associations between Peripheral Serotonin mRNA 
Expression and ATD Effects on Decision-Making
There was a significant positive correlation between baseline 
peripheral 5-HT1B mRNA levels and the ATD-induced increase 
(TRP- minus TRP+) in the overall proportion of experimental 
gambles chosen (r = .658, nominal P = .001, Bonferroni-corrected 
PBC = .041), with participants with higher baseline 5-HT1B tran-
scription levels displaying the greatest increase (Figure  1A). 
There was also a significant positive correlation between base-
line 5-HT1B transcription levels and the ATD-induced increase 
in win sensitivity (TRP- minus TRP+: r = .654, nominal P = .001, 
PBC = .045), with participants with higher baseline 5-HT1B tran-
scription levels displaying the greatest increase (Figure  1B). 
There was no other nominally significant correlation between 
peripheral 5-HT system mRNA levels and ATD-induced changes 
in decision-making.
Associations between Peripheral Serotonin mRNA 
Expression and ATD Effects on Anxiety
There was no significant correlation between peripheral tran-
scription levels of serotonin receptor mRNA and the ATD-
induced increase (TRP- T5 minus TRP- T0 scores) in state STAI 
scores (all P > .182).
Effect of Sex on Responses to ATD
We conducted exploratory analyses examining the effect of sex 
on treatment-induced changes in task performance. Results of 
the repeated-measures ANOVA revealed no significant interac-
tions between gender and treatment (F(1,24) = 1.848, P = .187), 
between gender, treatment, and sensitivity to probability 
(F(1,24) = .373, P = .547), between gender, treatment, and sensitiv-
ity to wins (F(1,24) = .083, P = .776), or between gender, treatment, 
and sensitivity to losses (F(1,24) = .028, P = .868).
We conducted exploratory analyses examining the effect 
of gender on the relationship between treatment-induced dif-
ferences in both win sensitivity and the overall proportion of 
experimental gambles chosen with baseline serotonin recep-
tor transcription levels. Regarding win sensitivity, there was an 
expected significant main effect of baseline 5HT1B transcription 
levels (F(1,17) = 11.697, P = .003) but no significant main effect 
of gender (F(1,17) = 1.334, P = .264) and no significant interac-
tion between baseline 5HT1B transcription levels and gender 
(F(1,17) = .201, P = .660). Regarding the overall proportion of exper-
imental gambles chosen, there was an expected significant 
main effect of baseline 5HT1B transcription levels (F(1,17) = 8.296, 
P = .010), but no significant main effect of gender (F(1,17) = 2.504, 
P = .132) and no significant interaction between baseline 5HT1B 
transcription levels and gender (F(1,17) = .2.575, P = .127). All mod-
els examining the effect of gender on the relationship between 
transcription levels of the remaining serotonin genes revealed 
no main effects of transcription levels or gender and no signifi-
cant interactions between transcription levels and gender.
Computational Analysis
We considered a family of models involving different poten-
tial influences of probability, reward, and expected value and 
included a trial-type independent choice bias parameter (some-
times called a lapse rate) to account for rare, unlikely decisions.
We first identified the most parsimonious model to param-
eterise performance on the decision-making task, independent 
of depletion condition. Widely Applicable Information Criterion 
Figure 1. Relationships between baseline peripheral serotonin (5-HT)1B mRNA levels and the treatment-induced increase (acute tryptophan depletion [ATD] minus 
sham) in the overall proportion of experimental gambles chosen (A) and the ATD-induced increase in sensitivity to wins (B).
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(WAIC) scores and log predictive densities (LPD) for the 5 models are 
displayed in supplementary Table 3. Model P+R (in which probabil-
ity and reward exert additive influences on choice; calibration plot 
in Figure 2A) is the winning model (lowest WAIC score). By contrast, 
model PxR, which parametrizes conventional utility theory (i.e., it 
assumes that subjects multiply probabilities by outcomes to calcu-
late the expected values for each option) performs poorly, reflected 
in its relatively high WAIC score and more negative LPD (denoting 
high deviation between model predictions and participants’ behav-
ior) (Figure  2B). The extra complexity of model P+R+(PxR), which 
allows for both additive and multiplicative influences of probability 
and reward, is not justified by the improved fit (less negative LPD), 
although the WAIC score is very close to that of model P+R.
After having recognized the most accurate model (P+R), 
we slightly refined the prior distributions over the sensitivity 
parameters and included a condition-independent lapse rate as 
described in the supplementary Materials (we denote this model 
P+’R). Total variation in choice frequencies (which was generally 
low, other than for 2 trial types, possibly limiting experimental 
sensitivity) is discussed in the SOM and depicted in supplemen-
tary Figure 3. The parameters associated with models PxR and 
P+’R are reported in Table  2. The close correspondence across 
subjects between participants’ actual and modelled sensitivities 
to probability, wins, and losses (from the winning model P+’R), 
displayed in supplementary Figure 2, suggests that the model 
accurately recapitulated the patterns observed in the raw data.
Consistent with the standard noncomputational analyses 
reported above, we found no significant effect of ATD on the 
computationally derived parameters from the winning P+’R 
model (Table 2; probability parameter: t(25) = 0.653 P = 0.520; win 
parameter: t(25) = 0.494, P = 0.626; loss parameter: t(25) = 1.540, 
P = 0.136). We also found no significant effect of ATD on other 
computationally obtained measures (lapse rate: t(25) = .052, 
P = 0.959; trial-type independent bias: t(25) = 1.889, P = 0.071).
Associations between Peripheral Serotonin mRNA 
Expression and ATD Effects on Decision-Making 
Assessed Using Computational Analysis
Finally, we assessed correlations between the effect of ATD on 
our fitted parameters (from model P+’R) and the transcripts 
discussed above. We found a positive correlation between the 
ATD-induced increase (TRP- minus TRP+) in the win parameter 
and peripheral 5-HT1B transcription levels (r = 0.654, nominal 
P = .001, Figure 3), which survives correction for multiple com-
parisons (PBC = .035) and mimics the correlation evident in the 
standard noncomputational analyses above (Figure 1B).
Discussion
Several studies have suggested that depleting central serotonin 
levels, via acute tryptophan depletion, affects reward process-
ing during decision-making (e.g., Rogers et  al., 2003; Seymour 
et al., 2012). However, no previous study has attempted to delin-
eate the roles of specific 5-HT receptors in this effect. We were 
unable to detect statistically significant effects of ATD on risky 
decision-making on the gambling task, contrary to the original 
report (Rogers et al., 2003). However, using an individual differ-
ences approach, we identified that higher baseline 5-HT1B mRNA 
levels in the blood predicted greater ATD-induced increases in 
both the number of experimental gambles chosen and sensi-
tivity to wins. This pattern was confirmed through detailed 
computational analysis. Our computational analysis also sug-
gested that, independent of ATD, subjects tend to perform this 
gambling task by treating information pertaining to probability, 
wins, and losses additively, not multiplicatively as would be pre-
dicted by standard utility theory.
The finding that ATD did not significantly affect participants’ 
discrimination between the magnitude of expected gains fails 
to corroborate the results of Rogers et al. (2003). The discrepancy 
between these results is unlikely to be due to the efficacy of the 
depletion; participants in the current study experienced, on 
average, a 73% decrease in plasma tryptophan levels, which is 
only 10% less than the decrease observed in Rogers et al. (2003) 
and is higher than the decrease in plasma tryptophan levels 
observed in other studies that show ATD to affect cognitive 
performance (e.g., Crockett et al., 2012). This difference is also 
unlikely to be related to design differences between the 2 stud-
ies. We used an identical task, though for many of the trial types 
we found that variability across participants and conditions 
(and therefore statistical sensitivity) was very low (supplemen-
tary Figure 3). Although we used a within-subjects design, we 
Figure 2. Calibration plots for models P+’R (A) and PxR (B). Red dots: tryptophan (TRP)- condition; blue dots: TRP+ condition. The x-axis represents model predictions 
(means of synthetic data derived using the best-fitting parameters); the y-axis the frequencies as computed from the raw data. Numbers indicate trial types (see sup-
plementary Materials for details) with 3 and 6 displayed in larger fonts to emphasize that they elicit more variability in responses; different colors of numbers indicate 
high (orange) and low (blue) probabilities of winning. Error bars indicate inter-subject standard errors as extracted from the raw data (vertical) and subject-level syn-
thetic data derived from model fits (horizontal).
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found little evidence for repetition effects on the task, and with 
26 participants we had >95% power to detect a “large” effect size 
of d~0.75 (Cohen et al., 1988), as reported by the original study.
Another possible reason for the discrepancy with the results 
of Rogers et  al. (2003) could be variation in the sample popu-
lations: There was a modest difference in mean age between 
subject samples, with the average age of the 26 participants 
included in our behavioral analyses being 29.5  years, while 
those in Rogers et al. (2003) were on average 23.8 years. However, 
there is no literature indicating that such a small age difference 
should account for the reported differences between results. 
There is some evidence, however, that ATD can have differing, 
and even directionally opposite effects, depending on trait char-
acteristics that were not measured in the current study, such 
as aggression (Bjork et  al., 2000) and a family history of alco-
holism (Crean et al., 2002). Given that the current results show 
peripheral levels of 5-HT1B mRNA to predict responses to ATD, 
it would be remiss to discount the influence of other such indi-
vidual differences.
The finding that peripheral 5-HT1B transcription levels were 
related to ATD-induced changes, in both the overall frequency 
of experimental gambles chosen and sensitivity to wins, pro-
vides direct evidence that peripheral 5-HT biomarkers can be 
used to predict responses to ATD. Apart from Ersche et al. (2011), 
who reported that variation in peripheral D3 receptor mRNA 
levels explained over one-quarter of the variance in pramipex-
ole-induced improvements on a spatial working memory task, 
attempting to predict inter-individual variation in cognitive 
responses to treatment by examining peripheral transcriptional 
biomarkers has not been done. Our results are the first to sug-
gest that such biomarkers can predict response to a treatment 
that acts directly on the serotonin system. With currently estab-
lished procedures that measure serotonin markers being both 
invasive and expensive (e.g., PET), it may be useful to obtain 
peripheral 5-HT markers when attempting to predict individual 
responses to clinical treatments that act upon the 5-HT system.
Very few studies have attempted to examine the roles of spe-
cific 5-HT receptors in decision-making in humans. For example, 
Macoveanu et al. (2013) reported that administering the 5-HT2A 
antagonist ketanserin increases risk aversion, and we (Faulkner 
et al., 2014) found that hippocampal 5-HT1A receptor availability 
is related to sensitivity to the probability of winning on the same 
gambling task adminsitered in the present study. However, 
while a link between decision-making and the 5HT1B receptor 
has been observed in mice (Pattij et al., 2003), very few studies 
have reported a relationship between risky decision-making and 
this receptor, particularly in humans. Potenza et al. (2011) report 
that greater 5-HT1B availability within the ventral striatum and 
putamen, as shown by PET, was related to greater scores on the 
South Oaks Gambling Screen in problem gamblers. In addition, 
Curley et al. (2013) showed that, compared with placebo, admin-
istration of the potent 5-HT1B agonist trifluoromethlyphenylpip-
erazine increased BOLD activation within the putamen when 
anticipating a reward during performance on a gambling task.
While these studies indicate a potential role for striatal 5-HT1B 
receptors in risky decision-making, the function of this receptor 
is thought to differ depending upon its location. For example, 
5-HT1B receptors within the striatum are thought to inhibit 5-HT 
release (Pytliak et al., 2011), whereas such receptors within the 
frontal cortex are thought to inhibit dopamine release (Sarhan 
et al., 1999). Decreases in both 5-HT and dopamine are thought 
to mediate risky decision-making and decrease the processing 
of information pertaining to rewards (see Rogers et al., 2011 for 
a review). Given that activity within the striatum and orbitofron-
tal cortex has often been associated with risky decision-making 
(e.g., Peters and Büchel, 2009), future studies could examine 
whether the observed correlation between 5-HT1B mRNA levels 
and ATD-induced changes in risky decision-making is mediated 
by activation changes within this circuit and by activity within 
the 5-HT or dopamine system.
This study has several limitations. First, while Ye et al. (2014) 
suggest that 5-HT receptor mRNA levels in blood are related to 
levels in the brain (midbrain and diencephalon) in mice, direct 
evidence for this in humans is lacking. While there are clear 
similarities between peripheral and brain levels of mRNA, varia-
tion between these 2 tissue types does exist (Sullivan et al., 2006, 
Le-Niculescu et al., 2009). However, Cattaneo et al. (2010) argue that 
treatment-induced increases in peripheral mRNA levels are a valid 
proxy for treatment-induced increases in mRNA levels in the brain 
by reporting that selective serotonin reuptake inhibitor-induced 
increases in peripheral neurotrophic factor mRNA in blood are 
comparable with such increases previously reported in brain 
(see Autry and Monteggia, 2012, for a review). However, the lack 
Table 2. Sample Means (SDs) for the Parameter Distributions (α) of 
Models PxR (multiplicative) and P+’R (Additive, the Winning Model) 
Including Lapse Rate
Model 
PxR  αPW  αPL Bias Lapse Rate
TRP- 1.59 (0.36) 1.77 (0.37) -0.08 (0.67) 0.28 (0.15)




TRP- 0.22 (0.10) 0.067 (0.008) 0.085 (0.022) 0.44 (0.62) 0.14 (0.16)
TRP+ 0.23 (0.10) 0.068 (0.007) 0.079 (0.016) 0.73 (0.68) 0.14 (0.17)
Abbreviations: L, loss; PL, probability*loss; PW, probability*win; W, win.
Descriptive statistics were computed using permuted samples from the 
posterior distributions of population parameters. Bias indicates the tendency 
to choose the experimental (when positive) or control gamble (when negative). 
The lapse rate column indicates the proportion of trials in which choice was 
inferred as being independent of trial-type (0, none, 1, all trials).
Figure  3. Correlation between peripheral serotonin (5-HT)1B mRNA levels and 
the acute tryptophan depletion (ATD)-induced increase (tryptophan [TRP]- 
minus TRP+) in the win parameter (from model P+’R).
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of direct evidence that 5-HT receptor mRNA levels in blood are 
related to those in the brain in humans means that work aimed 
at validating this approach could be useful. Second, while we 
attempted to examine transcription levels for 20 5-HT genes, due 
to low levels in the blood we were able to obtain reliable meas-
urements for only 9. The literature is beginning to shed light on 
the roles of 5-HT receptor subtypes other than 5-HT1B in decision-
making, such as the 5-HT1A and 5-HT2A (Macoveanu et al., 2013; 
Faulkner et al., 2014), and testing for the existence of relationships 
between risky decision-making and peripheral levels of mRNA for 
other 5-HT receptors could have proved useful. Third, the sample 
size used to assess the relationship between our peripheral mark-
ers and treatment-induced alteration in task performance was 
rather low. While the effect size was strong and we corrected for 
multiple comparisons to increase confidence in our findings, small 
sample sizes can sometimes overestimate effect sizes and replica-
tion may therefore be useful.
In summary, ATD did not significantly influence partici-
pants’ sensitivity to probability, wins, or losses, although there 
was a trend towards a lower general tendency to choose exper-
imental gambles following depletion. As such, our adequately 
powered study failed to replicate the results of Rogers et  al. 
(2003), in which depletion decreased participants’ ability to dis-
criminate between the magnitudes of expected gains. However, 
following ATD, participants with higher peripheral 5-HT1B tran-
scription levels increased their overall choice of experimental 
gambles (relative to sham depletion) and used information 
pertaining to possible wins more when making their choices, 
a result that was confirmed through detailed computational 
analyses. These results suggest that the 5-HT1B receptor may 
modulate the effects of ATD on risky decision-making and 
indicate the utility of using peripheral 5-HT system mRNA lev-
els to predict the efficacy of treatments that perturb this neu-
rotransmitter system.
Supplementary Material
For supplementary material accompanying this paper, visit 
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